625
Views & Citations10
Likes & Shares
Biomarker is a biomolecule
that is objectively measured and evaluated as an indicator of normal biological
processes, pathological processes, or pharmacological responses to a
therapeutic drug treatment [1,2]. Alternatively, it can be defined as a chemical,
its metabolite, or the product of an interaction between a chemical and some
target molecule (genes, gene products, enzymes or hormones, etc.) or cell that
is measured in the human body. The effectiveness of a biomarker is determined
by the degree to which biomarker reflect clinical outcomes. Therefore, an ideal
biomarker is expected to be: (i) able to detect a fundamental feature of a
specific disease, validated in and confirmed by those specific disease cases;
(ii) able to detect the early stages of this specific disease and differentiate
it from other similar disease cases or family members of that disease; (iii)
precise, accurate, sensitive, specific, non-invasive and inexpensive [3].
Disease-related biomarkers
[4] indicate the probable effect of treatment on patient (predictive
biomarkers), if a disease already exists (diagnostic biomarker), or how such a
disease may develop in an individual case regardless of the type of treatment
(prognostic biomarker).
Biomarkers can be classified
into:
1.
Electrolytes and ions - sodium (Na+), potassium (K+),
chloride (Cl-), carbondioxide (CO2), calcium (Ca2+),
phosphorus (phosphate, PO43-), magnesium (Mg2+),
iron (Fe2+).
2.
Small molecules and metabolites (under a molecular weight of 1000) - those
that reflect nutritional status (glucose, vitamin B12, folic acid, etc.), those
that reflect the elimination of waste products (bilirubins, lactic acid,
creatinine, uric acid, urea nitrogen, ammonia, etc.) and those that reflect
metabolic control (thyroid stimulating hormone, estrogen, testosterone,
beta-human chorionic gonadotropin, etc.)
3.
Large molecules and metabolites (molecular weights ranging from 30,000 to
over 500,000) - plasma proteins (albumin, globulins, prealbumin), transport
proteins (ferritin, transferring, haptoglobin ceruloplasmin), defense proteins
(immunoglobulins IgA, IgG, IgM, IgE, complements C3, C4), clotting proteins
(fibrinogen, D-dimer), enzymes (alanine aminotransferase ALT, aspartate
aminotransferase AST, alanine phosphatase ALP, gamma-glutamyltransferase,
lactate hydrogenase LD, creatine kinase CK, amylase, lipase and
pseudocholinesterase), tumor markers (prostate specific antigen PSA,
carcinoembryonic antigen CEA, cancer antigen 125 CA125, cancer antigen 15-3
CA15-3, alpha-fetoprotein AFP, rheumatoid factor RF, C-reactive protein CRP,
high sensitivity C-reactive protein hsCRP, beta natriuretic peptide β-NP and
antistreptolysin-O ASO).
4.
Lipids and lipoproteins - (total cholesterol, high density lipoprotein HDL
cholesterol, low density lipoprotein LDL cholesterol, triglycerides,
lipoprotein a, apopoproptein A and B).
5.
Hypothesis-driven - quiescin Q6 sulfhydryl oxidase 1 (QSOX-1). It is a
protein and the most promising candidate to identify patients with acute
decompensated heart failure (ADHF).
6.
Genetic - These biomarkers are based on the determination of genetic
polymorphisms and can be either of intake or of effect (metabolism) or as
disease risk. They can be determined in the DNA of any biological sample that contains
cells with a nucleus.
7.
Environmental - biomarkers that measure exposure in the human body
(cotinine in blood or urine for second-
These biomarkers can be found in biological samples such
as blood (whole blood, plasma or serum), urine, saliva, cerebrospinal fluid, amniotic fluid, synovial
fluid, pleural fluid, pericardial fluid, peritoneal fluid (ascetic fluid),
faeces, hair, nails, adipose tissue and other specific tissues depending on the
aims of the study.
A human serum is the clear portion of the human’s body
fluid that separates from blood upon clotting. The serum contains proteins
(60-80 mg/ml) in addition to various small molecules such as amino acids,
lipids, salts and sugars [5]. Human serum contains numerous biomarkers for a
number of diseases such as cancer, cardiovascular, rheumatoid arthritis,
respiratory, neurodegenerative, etc. Typical examples are prostatic acid
phosphatase [6] and PSA [7] for prostate cancer; carcinoembryonic antigen CEA
[8], for colorectal, lung, breast, liver, pancrease, bladder cancers and CA 125
[9] for ovarian cancer, etc. Serum biomarkers for cardiovascular disease are
B-type natriuretic peptide, nesiritide [10], N-terminal proB-type natriuretic
peptide [11] and C-reactive protein [12], etc. Rheumatoid arthritis has
stromelysin-1 [13], interleukin-15 [14] and
cytokines tumor necrosis factor-α, interleukins-12, -15, and -18 [15] as
serum biomarkers. The respiratory serum biomarkers are
urinary-trypsin-inhibitor [16], eosinophil cationic protein [17] while cystic
fibrosis (CF) has serum CA 19-9 [18], trypsinogen [19] and prolyl hydroxylase
serum [20], etc. as biomarkers.
Due to the high abundance of albumin and heterogeneity
of plasma lipoproteins and glycoproteins, biomarkers are difficult to identify
and quantify in human serum. Therefore, analytical method to be adopted has to
be accurate, precise, selective, specific and sensitive. Biomarkers that are
proteins have been separated, identified and quantified from crude biological
samples by using analytical methods which exploit the physicochemical
properties (isoelectric point, hydrophobicity and molecular mass and size) of
proteins. Separation based on isolelectric point is done using ion exchange
chromatography [21] as well as gel electrophoresis [22,23]. Separation based on
hydrophobicity is carried out using reversed phase high performance liquid
chromatography, RP-HPLC [24]. Separation based on molecular mass and size is
done using gel electrophoresis as well as size exclusion chromatography [25].
Other methods utilized for protein analysis are immunological techniques [26],
mass spectrometry techniques [27], tandem-mass spectrometry [28], liquid
chromatography-mass spectrometry [29]. In addition, analytical methodologies
for the determination serum biomarkers that are not proteins include atomic
absorption spectrometry, inductively coupled plasma spectrometry, liquid
chromatography (LC), gas chromatography (GC), mass spectrometry(MS) and
hyphenated systems (GC-MS, LC-MS/MS techniques), etc.
In conclusion, biomarkers (chemical, physical or
biological) play major roles in medicinal biology and help in early diagnosis,
disease prevention, drug target identification and drug response. They are
useful in measuring the progress of disease, evaluating the most effective
therapeutic regimes for a particular disease and establish a long-term
susceptibility to disease or its recurrence. Currently, techniques such as
genomics, proteomics, metabolomics, lipidomics, glycomics, secretomics are also
being employed to accurately measure the disease biomarker levels and establish
criteria for disease diagnosis and prognosis. Finally, to enhance future serum
biomarker identification and quantification, techniques should be improved and
combinations of different technologies and statistical analysis are required to
increase the accuracy, sensitivity, reproducibility and specificity of
biomarker detection.
1. Malchow
S, Loosse C, Sickmann A, Lorenz C (2017) Quantification of cardiovascular
disease biomarkers in human platelets by targeted mass spectrometry. Proteomes
5: 31-44.
2. Atkinson
AJ, Colburn WA, DeGruttola VG. (2001). Biomarkers and surrogate endpoints:
Preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
3. de
Vries J, Antoine JM, Burzykowski T, Chiodini A, Gibney M, et al. (2013) Markers
for nutrition studies: Review of criteria for the evaluation of markers. Eur J
Nutr 52: 1685-1699.
4. Tevak
Z, Kondratovich M, Mansfield E (2010) In
vitro diagnostic regulatory perspective. Personalized Medicine 7: 517-530.
5. Anderson
NL, Anderson NG (2002). The human plasma proteome - History, character and
diagnostic prospects. Mol Cell Proteomics 1: 845-867.
6. Yam
LT (1974) Clinical significance of the human acid phosphatases: Review. Am J
Med 56: 604-616.
7. Miyata
Y, Sakai H, Hayashi T (2003) Serum insulin-like growth factor binding
protein-3/prostate-specific antigen ratio is a useful predictive marker in
patients with advanced prostate cancer. Prostate 54: 125-132.
8. Williams
MR, Turkes A, Pearson D, Twining P, Griffiths K, et al. (1988) The use of serum
carcinoembryonic antigen to assess therapeutic response in locally advanced and
metastatic breast-cancer: A prospective-study with external review. Eur J Surg
Oncol 14: 417-422.
9. Whitehouse
C, Solomon E (2003) Current status of the molecular characterization of the
ovarian cancer antigen CA125 and implications for its use in clinical
screening. Gynecol Oncol 88: S152-S157.
10. McCullough
PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, et al. (2002) B-type
natriuretic peptide and clinical judgment in emergency diagnosis of heart
failure - Analysis from breathing not properly (BNP) multinational study.
Circulation 106: 416-422.
11. Nasser
N, Bar-Oz B, Nir A (2005) Natriuretic peptides and heart disease in infants and
children. J Pediatr 147: 248-253.
12. Rifai
N, Ridker PM (2001) High-sensitivity C-reactive protein: A novel and promising
marker of coronary heart disease. Clin Chem 47: 403-411.
13. Yamanaka
H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, et al. (2000) Serum matrix
metalloproteinase 3 as a predictor of the degree of joint destruction during
the six months after measurement, in patients with early rheumatoid arthritis.
Arthritis Rheum 43: 852-858.
14. Cao
LF, Lu YM, Ma M, Xue HY, Zhao Y, et al. (2006) Levels of serum interleukin-15
and the expression of T-helper lymphocyte subsets in peripheral blood of
children with juvenile rheumatoid arthritis. Chinese J Contemp Pediatr 8: 9-12.
15. Petrovic-Rackov
L (2006) Evaluation of the degree of clinical rheumatoid arthritis activity
based on the concentrations of cytokines TNF-alpha, IL-12, IL-15 and IL-18 in
serum and synovial fluid. Vojnosanit Pregl 63: 21-26.
16. Yasui
K, Kanda H, Iwanami T, Komiyama A (2003) Increased serum concentration of
urinary trypsin inhibitor with asthma exacerbation. Eur Respir J 22: 739-742.
17. Sorkness
C, McGill K, Busse WW (2002) Evaluation of serum eosinophil cationic protein as
a predictive marker for asthma exacerbation in patients with persistent
disease. Clin Exptal Allerg 32: 1355-1359.
18. Duffy
MJ, Osullivan F, McDonnell TJ, FitzGerald MX (1985) Increased concentrations of
the antigen Ca-19–9 in serum of cystic-fibrosis patients. Clin Chem 31:
1245-1246.
19. Cleghorn
G, Benjamin L, Corey M, Forstner G, Dati F, et al. (1985) Age-related
alterations in immunoreactive pancreatic lipase and cationic trypsinogen in
young-children with cystic-fibrosis. J Pediatr 107: 377-381.
20. Pereira
TN, Lewindon PJ, Smith JL, Murphy TL, Lincoln DJ, et al. (2004) Serum markers
of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol 41:
576-583.
21. Shan
L, Anderson DJ (2002) Gradient chromatofocusing. Versatile pH gradient
separation of proteins in ion-exchange HPLC: Characterization studies. Anal
Chem 74: 5641-5649.
22. Sahab
Ziad J, Suh Y, Sang Qing-Xiang A (2005). Isoelectric point-based
prefractionation of proteins from crude biological samples prior to
two-dimensional gel electrophoresis. J Proteome Res 4: 2266-2272.
23. Lilley
KS, Razzaq A, Dupree P (2002) Two-dimensional gel electrophoresis: recent
advances in sample preparation, detection and quantitation. Curr Opin Chem Biol
6: 46-50.
24. Sheng
S, Chen D, Van Eyk JE (2006) Multidimensional liquid chromatography separation
of intact proteins by chromatographic focusing and reversed phase of the human
serum proteome - Optimization and protein database. Mol Cell Proteomics 5:
26-34.
25. Bloustine
J, Berejnov V, Fraden S (2003). Measurements of protein-protein interactions by
size exclusion chromatography. Biophys J 85: 2619-2623.
26. Moody
MD, Van Arsdell SW, Murphy KP, Orencole SF, Burns C (2001) Array-based ELISAs
for high-throughput analysis of human cytokines. Biotechnique 31: 186-187.
27. Heck
AJR, Krijgsveld J (2004) Mass spectrometry-based quantitative proteomics. Exp
Rev Proteomics 1: 317-326.
28. Dongre
AR, Eng JK, Yates JR (1997). Emerging tandem mass spectrometry techniques for
the rapid identification of proteins. Trends Biotechnol 15: 418-425.
29. Fung
KYC, Askovic S, Basile F, Duncan MW (2004) A simple and inexpensive approach to
interfacing high-performance liquid chromatography and matrix-assisted laser
desorption/ionization-time of flight-mass spectrometry. Proteomics 4:
3121-3127.